Floatz logo

su011248

Urologic Neoplasms

AstraZenecaPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Urologic Neoplasms cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
VOLITINIB
AstraZeneca
Phase 3B
MOTEXAFIN GADOLINIUM HYDRATE
Phase 2B
Palbociclib
NiKang Therapeutics, Inc.
Phase 2CCC
Tucatinib
Seagen, a wholly owned subsidiary of Pfizer
Phase 2CCC

View all 24 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →